What is PLRZ's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PLRZ?

P/E (TTM) is n/a and 52-week range is $2.88 to $18.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PLRZ figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PLRZ?

The company profile lists net income (TTM) near $-12M, EPS (TTM) near $-5.64 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Polyrizon Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ra'anana, Central(HaMerkaz), IL, 2.1M shares outstanding, ISIN IL0011814113 when available from company profile and filing metadata.

Polyrizon Ltd (PLRZ) Stock Analysis, Quote & Company Profile

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. The company is headquartered in Ra'Anana, Central(Hamerkaz) and currently employs 1 full-time employees. The company went IPO on 2024-10-29. The firm is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The firm is focused not only on the development of intranasal products, but also on commercialization. The firm cooperates with medical specialists and researchers..

Employees

Website

polyrizon-biotech.com/

IPO

2024-10-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)